INCR
InterCure Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$5.42
+3.04%Aug 24, 2026, 11:00 UTC
InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, and plans to accelerate rehabilitation of Canndoc's Nir Oz facility.
Source:Jun 22, 2026, 12:50 UTC
InterCure Ltd. secured NIS 22 million in private placement financing from investors including its CEO and pharma-focused hedge funds.
Source:Jun 15, 2026, 13:25 UTC
InterCure completed the initial closing of its acquisition of Botanico, gaining exclusive access to U.S. genetics, premium brands, and AI-driven technologies.
Source: